Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.82 |
| ▸ | HTT | P42858 | 2/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | ME1 | P48163 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24323763 | 0.84 | POLB (0.76) | GAASMN1; SMN2MAPK1HTTALDH1A1 | |
| SCHEMBL14986321 | 0.75 | MAPK1 (0.46) | GAASMN1; SMN2MAPK1HTTALDH1A1 | |
| SCHEMBL22571079 | 0.73 | GAA (0.64) | GAASMN1; SMN2MAPK1HTTALDH1A1 | |
| SCHEMBL22571078 | 0.73 | GAA (0.64) | GAASMN1; SMN2MAPK1HTTALDH1A1 | |
| SCHEMBL18181914 | 0.73 | GAA (0.64) | GAASMN1; SMN2MAPK1HTTALDH1A1 | |
| SCHEMBL18177887 | 0.73 | SMN1; SMN2 (1.00) | GAASMN1; SMN2MAPK1HTTALDH1A1 | |
| SCHEMBL22426230 | 0.72 | ALDH1A1 (0.72) | GAASMN1; SMN2MAPK1HTTALDH1A1 | |
| SCHEMBL22426229 | 0.72 | ALDH1A1 (0.72) | GAASMN1; SMN2MAPK1HTTALDH1A1 | |
| SCHEMBL22426227 | 0.71 | POLB (0.72) | GAASMN1; SMN2MAPK1HTTALDH1A1 | |
| SCHEMBL22426228 | 0.71 | POLB (0.72) | GAASMN1; SMN2MAPK1HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | GAA 1981/4885SMN1; SMN2 4226/4885MAPK1 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.